SCHEMBL5569457

SCHEMBL5569457

CNC(=O)c1cc(Oc2cccc(NC(=O)Nc3ccc(Cl)c(OCCN4CCCC4)c3C(F)(F)F)c2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.61
RAF1 P04049 13/20 0.54
BRAF P15056 6/20 0.54
KDR P35968 5/20 0.54
MAPK14 Q16539 4/20 0.54
ABL1 P00519 3/20 0.54
EPHA2 P29317 3/20 0.54
MAP3K20 Q9NYL2 3/20 0.54
EPHX2 P34913 3/20 0.54
RIPK2 O43353 2/20 0.54
ABCB11 O95342 2/20 0.54
HTR1A P08908 2/20 0.54
PDGFRB P09619 2/20 0.54
ADORA3 P0DMS8 2/20 0.54
KIT P10721 2/20 0.54
FGFR1 P11362 2/20 0.54
PDGFRA P16234 2/20 0.54
FLT1 P17948 2/20 0.54
MAOA P21397 2/20 0.54
EPHA1 P21709 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565121 0.94 RET (0.59) RETRAF1BRAFKDRMAPK14
SCHEMBL5564860 0.94 RET (0.59) RETRAF1BRAFKDRMAPK14
SCHEMBL5569618 0.93 RAF1 (0.60) RETRAF1BRAFKDRMAPK14
SCHEMBL5569608 0.89 RET (0.57) RETRAF1BRAFKDRMAPK14
SCHEMBL5569455 0.89 RET (0.61) RETRAF1BRAFKDRMAPK14
SCHEMBL5570160 0.88 RET (0.66) RETRAF1BRAFKDRMAPK14
SCHEMBL5565379 0.87 RET (0.64) RETRAF1BRAFKDRMAPK14
SCHEMBL5569605 0.87 RET (0.60) RETRAF1BRAFKDRMAPK14
SCHEMBL5569279 0.87 RAF1 (0.63) RETRAF1BRAFKDRMAPK14
SCHEMBL5568221 0.87 RAF1 (0.58) RETRAF1BRAFKDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A 2007-07-19 JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 EP disclosed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS RET 40/4885RAF1 2/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.